Meng Wenfang, Xue Shihang, Chen Ye
Division of Medical Genetics and Genomics, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Institute of Genetics, Zhejiang University, Hangzhou, Zhejiang, China.
Ningbo No.4 People's Hospital, Ningbo, Zhejiang, China.
Gene. 2018 Jan 30;641:105-110. doi: 10.1016/j.gene.2017.10.015. Epub 2017 Oct 7.
The chemokine ligand C-X-C motif chemokine ligand 12 (CXCL12) is a kind of small molecules of cytokines that widely expressed in diversified tissues. Recent evidence suggests that CXCL12 plays an important role in the communication of tumor cells with their surrounding microenvironment. The interaction of CXCL12 and its receptors subsequently excite the downstream signaling pathways to affect tumor angiogenesis, tumor cell proliferation and chemoresistance, and thus represents a potential target for cancer therapy. Outpouring molecules targeting CXCL12/CXCR4 axis in tumor microenvironment combined with traditional chemotherapy have drawn more and more attentions, which will be a promising method in anti-cancer therapies. Our review focuses on these roles of CXCL12 and summarizes strategies for treating cancer by disrupting this interaction with special emphasis on the CXCR4/CXCL12 axis.
趋化因子配体C-X-C基序趋化因子配体12(CXCL12)是一种在多种组织中广泛表达的小分子细胞因子。最近的证据表明,CXCL12在肿瘤细胞与其周围微环境的通讯中起重要作用。CXCL12与其受体的相互作用随后激活下游信号通路,影响肿瘤血管生成、肿瘤细胞增殖和化疗耐药性,因此是癌症治疗的一个潜在靶点。在肿瘤微环境中靶向CXCL12/CXCR4轴的大量分子与传统化疗相结合已越来越受到关注,这将是抗癌治疗中的一种有前景的方法。我们的综述重点关注CXCL12的这些作用,并总结通过破坏这种相互作用来治疗癌症的策略,特别强调CXCR4/CXCL12轴。